Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need.
As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more about our neuromuscular franchise at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.
The Senior Director / Director, Global Medical Affairs (Evidence Generation), reporting to the VP, Global Medical Affairs, will lead the development and execution of the global evidence generation strategy to support market access, reimbursement, value demonstration, and scientific communication for commercial and pipeline products within the Scholar Rock portfolio.
This individual will serve as the global subject matter expert for evidence generation, responsible for identifying evidence gaps, establishing integrated evidence generation plans, and ensuring the successful execution and dissemination of evidence that demonstrates the clinical, economic, and patient-centered value of Scholar Rock therapies. The role requires strong strategic leadership and cross-functional collaboration with Medical Affairs, Clinical Development, Market Access, Commercial, HEOR, and regional teams to optimize product differentiation and support access for patients worldwide.
The successful candidate will partner closely with global and regional stakeholders to generate evidence that informs healthcare decision-making among healthcare professionals, payers, health technology assessment (HTA) bodies, health systems, advocacy organizations, and other key stakeholders.
Scholar Rock is an Equal Opportunity Employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock on X.
For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/
For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy/
